Identification

Name
Benzatropine
Accession Number
DB00245  (APRD00748)
Type
Small Molecule
Groups
Approved
Description

Benzotropine is a centrally-acting, antimuscarinic agent used as an adjunct in the treatment of Parkinson’s disease. It may also be used to treat extrapyramidal reactions, such as dystonia and Parkinsonism, caused by antipsychotics (e.g. phenothiazines). Symptoms of Parkinson’s disease and extrapyramidal reactions arise from decreases in dopaminergic activity which creates an imbalance between dopaminergic and cholinergic activity. Anticholinergic therapy is thought to aid in restoring this balance leading to relief of symptoms. In addition to its anticholinergic effects, benztropine also inhibits the reuptake of dopamine at nerve terminals via the dopamine transporter. Benzotropine also produces antagonistic effects at the histamine H1 receptor.

Structure
Thumb
Synonyms
  • 3-alpha-(diphenylmethoxy)tropane
  • 3alpha-(Diphenylmethoxy)-1alphah,5alphah-tropane
  • 3alpha-(Diphenylmethoxy)tropane
  • 3alpha-Benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
  • 3endo-benzhydryloxytropane
  • 3α-(diphenylmethoxy)-1αH,5αH-tropane
  • 3α-(diphenylmethoxy)tropane
  • 3α-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
  • Benzatropina
  • Benzatropinum
  • Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether
  • Benztropine
  • Tropine Benzohydryl Ether
External IDs
NK-02
Product Ingredients
IngredientUNIICASInChI Key
Benzatropine mesylateWMJ8TL7510132-17-2CPFJLLXFNPCTDW-BWSPSPBFSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bensylate Tab 2mgTablet2 mgOralIcn Pharmaceuticals1978-12-312005-04-26Canada
Benztropine 2 Tab 2mgTablet2 mgOralPro Doc Limitee1982-12-312009-07-23Canada
Benztropine MesylateInjection1 mg/mLIntramuscular; IntravenousTYA Pharmaceuticals2012-08-08Not applicableUs
Benztropine MesylateInjection1 mg/mLIntramuscular; IntravenousAkorn2012-08-08Not applicableUs
Benztropine Mesylate Injection, USPLiquid1 mgIntramuscular; IntravenousSabex IncNot applicableNot applicableCanada
Benztropine OmegaLiquid1 mgIntramuscular; IntravenousOmega Laboratories Ltd1999-05-28Not applicableCanada
CogentinInjection1 mg/mLIntramuscular; IntravenousOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)1959-08-05Not applicableUs
Cogentin Inj 1mg/mlSolution1 mgIntramuscular; IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312004-07-29Canada
Cogentin Tab 2mgTablet2 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1954-12-312003-01-29Canada
Dom-benztropineTablet2 mgOralDominion PharmacalNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benztropine MesylateTablet.5 mg/1OralAmerincan Health Packaging2009-11-01Not applicableUs
Benztropine MesylateTablet2 mg/1OralQualitest2007-08-27Not applicableUs
Benztropine MesylateTablet.5 mg/1OralAphena Pharma Solutions Tennessee, Inc.2007-08-27Not applicableUs
Benztropine MesylateTablet2 mg/1OralMajor2006-02-16Not applicableUs00904 1057 61 nlmimage10 293294f4
Benztropine MesylateTablet1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-11-28Not applicableUs
Benztropine MesylateTablet.5 mg/1OralRemedy Repack2011-09-202016-11-11Us
Benztropine MesylateInjection1 mg/mLIntramuscular; IntravenousZydus Pharmaceuticals Usa, Inc.2015-05-18Not applicableUs
Benztropine MesylateTablet2 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Benztropine MesylateInjection1 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2009-09-01Not applicableUs
Benztropine MesylateTablet2 mg/1OralBayshore Pharmaceuticals Llc (Nj)2012-11-28Not applicableUs
International/Other Brands
Apo-Benztropine (Apotex) / Cogentinol (Astra (Germany, discontinued)) / PMS Benztropine (Pharmascience)
Categories
UNII
1NHL2J4X8K
CAS number
86-13-5
Weight
Average: 307.4293
Monoisotopic: 307.193614427
Chemical Formula
C21H25NO
InChI Key
GIJXKZJWITVLHI-PMOLBWCYSA-N
InChI
InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+
IUPAC Name
(1R,3R,5S)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane
SMILES
[H][[email protected]]12CC[[email protected]]([H])(C[[email protected]@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C

Pharmacology

Indication

For use as an adjunct in the therapy of all forms of parkinsonism and also for use in the control of extrapyramidal disorders due to neuroleptic drugs.

Structured Indications
Pharmacodynamics

Benztropine is an anticholinergic used in the symptomatic treatment of all etiologic groups of parkinsonism and drug-induced extrapyramidal reactions (except tardive dyskinesia). Benztropine possesses both anticholinergic and antihistaminic effects, although only the former has been established as therapeutically significant in the management of parkinsonism. Benztropine's anticholinergic activity is about equal to that of atropine. Benztropine also inhibits dopamine reuptake via the dopamine transporter at nerve terminals.

Mechanism of action

Benztropine is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Benztropine partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
ASodium-dependent dopamine transporter
inhibitor
Human
UHistamine H1 receptor
antagonist
Human
Absorption

Onset of action is 1-2 hours following oral administration. The onset of action is within minutes when administered by IM or IV injection.

Volume of distribution
Not Available
Protein binding

~95% to serum proteins

Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Signs of overdose include confusion, nervousness, listlessness, hallucinations, dizziness; muscle weakness, ataxia, dry mouth, mydriasis, blurred vision, palpitations, tachycardia, elevated blood pressure, nausea, vomiting, dysuria, numbness of fingers, headache, delirium, coma, shock, convulsions, respiratory arrest, anhidrosis, hyperthermia, glaucoma, and constipation.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Benzatropine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Benzatropine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Benzatropine.Experimental, Illicit
AbirateroneThe serum concentration of Benzatropine can be increased when it is combined with Abiraterone.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Benzatropine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Benzatropine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Ambenonium.Approved
AmiodaroneThe metabolism of Benzatropine can be decreased when combined with Amiodarone.Approved, Investigational
AmphetamineAmphetamine may decrease the sedative activities of Benzatropine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Anisotropine Methylbromide.Approved
ArmodafinilThe metabolism of Benzatropine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Benzatropine can be decreased when combined with Artemether.Approved
AtomoxetineThe metabolism of Benzatropine can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Benzatropine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Benzatropine.Approved, Illicit
Benzylpenicilloyl PolylysineBenzatropine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Benzatropine.Approved
BetaxololThe metabolism of Benzatropine can be decreased when combined with Betaxolol.Approved
BezitramideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Benzatropine is combined with Biperiden.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Bornaprine.Experimental
BortezomibThe metabolism of Benzatropine can be decreased when combined with Bortezomib.Approved, Investigational
Botulinum Toxin Type ABenzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BBenzatropine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Benzatropine can be decreased when combined with Bupropion.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Benzatropine can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Benzatropine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CelecoxibThe metabolism of Benzatropine can be decreased when combined with Celecoxib.Approved, Investigational
ChloramphenicolThe metabolism of Benzatropine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Benzatropine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Benzatropine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Chlorphenoxamine.Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative activities of Benzatropine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Benzatropine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Benzatropine.Approved
CholecalciferolThe metabolism of Benzatropine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Benzatropine can be decreased when combined with Cimetidine.Approved
CimetropiumBenzatropine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinacalcetThe metabolism of Benzatropine can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Benzatropine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Benzatropine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Benzatropine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Benzatropine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Benzatropine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Benzatropine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Benzatropine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Benzatropine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Benzatropine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Benzatropine is combined with Cyclopentolate.Approved
DabrafenibThe serum concentration of Benzatropine can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Benzatropine is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Benzatropine can be increased when it is combined with Darunavir.Approved
DecamethoniumThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Decamethonium.Approved
DelavirdineThe metabolism of Benzatropine can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Demecarium.Approved
DesipramineThe metabolism of Benzatropine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dexetimide.Withdrawn
DextroamphetamineDextroamphetamine may decrease the sedative activities of Benzatropine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dicyclomine.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Benzatropine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydromorphine.Experimental, Illicit
DiphenhydramineThe metabolism of Benzatropine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Benzatropine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Donepezil.Approved
DosulepinThe metabolism of Benzatropine can be decreased when combined with Dosulepin.Approved
DPDPEThe risk or severity of adverse effects can be increased when Benzatropine is combined with DPDPE.Investigational
DronabinolBenzatropine may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Benzatropine can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Benzatropine can be decreased when combined with Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe metabolism of Benzatropine can be decreased when combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Benzatropine can be decreased when combined with Eliglustat.Approved
EluxadolineBenzatropine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Emepronium.Experimental
Eslicarbazepine acetateThe metabolism of Benzatropine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Benzatropine can be decreased when combined with Esomeprazole.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Benzatropine can be decreased when combined with Etravirine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fesoterodine.Approved
FluconazoleThe metabolism of Benzatropine can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Benzatropine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Benzatropine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Benzatropine can be increased when combined with Fosphenytoin.Approved
GalantamineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Gallamine Triethiodide.Approved
GemfibrozilThe metabolism of Benzatropine can be decreased when combined with Gemfibrozil.Approved
GepefrineGepefrine may decrease the sedative activities of Benzatropine.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Benzatropine is combined with Glucagon recombinant.Approved
GlycopyrroniumBenzatropine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HaloperidolThe metabolism of Benzatropine can be decreased when combined with Haloperidol.Approved
HeroinThe risk or severity of adverse effects can be increased when Benzatropine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benzatropine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Benzatropine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Benzatropine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hyoscyamine.Approved
ImipramineThe metabolism of Benzatropine can be decreased when combined with Imipramine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Benzatropine.Approved
IndinavirThe metabolism of Benzatropine can be decreased when combined with Indinavir.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Benzatropine.Approved
Ioflupane I-123Benzatropine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IpidacrineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium bromide.Approved
IsoflurophateThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Benzatropine can be decreased when combined with Isoniazid.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Benzatropine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Benzatropine can be decreased when combined with Ketoconazole.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Benzatropine is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Levorphanol.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Benzatropine.Approved, Investigational
LobeglitazoneThe metabolism of Benzatropine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Benzatropine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Benzatropine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Benzatropine can be decreased when combined with Lorcaserin.Approved
LuliconazoleThe serum concentration of Benzatropine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Benzatropine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Benzatropine can be decreased when combined with Lumefantrine.Approved
MalathionThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineThe metabolism of Benzatropine can be decreased when combined with Manidipine.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Memantine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Benzatropine.Investigational
MephentermineMephentermine may decrease the sedative activities of Benzatropine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Meptazinol.Experimental
MethadoneThe metabolism of Benzatropine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Benzatropine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Benzatropine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Methantheline.Approved, Investigational
MethotrimeprazineThe metabolism of Benzatropine can be decreased when combined with Methotrimeprazine.Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Benzatropine.Experimental
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Benzatropine.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Benzatropine.Approved
MetoprololThe metabolism of Benzatropine can be decreased when combined with Metoprolol.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Benzatropine.Approved, Investigational
MidomafetamineMidomafetamine may decrease the sedative activities of Benzatropine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Benzatropine can be decreased when combined with Midostaurin.Approved
MinaprineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mirabegron.Approved
MMDAMMDA may decrease the sedative activities of Benzatropine.Experimental, Illicit
MoclobemideThe metabolism of Benzatropine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Benzatropine can be decreased when combined with Modafinil.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Morphine.Approved, Investigational
NabiloneBenzatropine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Nalbuphine.Approved
NelfinavirThe metabolism of Benzatropine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NevirapineThe metabolism of Benzatropine can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Benzatropine can be decreased when combined with Nicardipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Nicomorphine.Experimental
NilotinibThe metabolism of Benzatropine can be decreased when combined with Nilotinib.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Normethadone.Approved, Illicit
OmeprazoleThe metabolism of Benzatropine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpiumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Orphenadrine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxyphenonium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Benzatropine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Benzatropine can be decreased when combined with Pantoprazole.Approved
ParaoxonThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Paraoxon.Experimental
ParoxetineThe metabolism of Benzatropine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Benzatropine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Phenglutarimide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Phenoperidine.Experimental
PhenterminePhentermine may decrease the sedative activities of Benzatropine.Approved, Illicit
PhenytoinThe metabolism of Benzatropine can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Benzatropine.Approved
Potassium ChlorideBenzatropine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Benzatropine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Procyclidine.Approved
PromazineThe metabolism of Benzatropine can be decreased when combined with Promazine.Approved, Vet Approved
PropanthelineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Propiverine.Approved, Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Benzatropine.Approved
PyridostigmineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Benzatropine.Approved
QuinidineThe metabolism of Benzatropine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Benzatropine can be decreased when combined with Quinine.Approved
RamosetronBenzatropine may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe metabolism of Benzatropine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Benzatropine is combined with Remifentanil.Approved
RifampicinThe metabolism of Benzatropine can be increased when combined with Rifampicin.Approved
RitobegronRitobegron may decrease the sedative activities of Benzatropine.Investigational
RitonavirThe metabolism of Benzatropine can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Benzatropine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Benzatropine can be decreased when combined with Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Benzatropine.Approved, Investigational
SertralineThe metabolism of Benzatropine can be decreased when combined with Sertraline.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Benzatropine is combined with Solifenacin.Approved
StiripentolThe metabolism of Benzatropine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benzatropine.Approved, Investigational
TacrineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tapentadol.Approved
TerbinafineThe metabolism of Benzatropine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
ThioridazineThe metabolism of Benzatropine can be decreased when combined with Thioridazine.Approved, Withdrawn
TiclopidineThe metabolism of Benzatropine can be decreased when combined with Ticlopidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tilidine.Experimental
TiotropiumBenzatropine may increase the anticholinergic activities of Tiotropium.Approved
TipranavirThe metabolism of Benzatropine can be decreased when combined with Tipranavir.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Benzatropine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tramadol.Approved, Investigational
TranylcypromineThe metabolism of Benzatropine can be decreased when combined with Tranylcypromine.Approved
TrichlorfonThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Benzatropine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Benzatropine is combined with Trihexyphenidyl.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Benzatropine is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Benzatropine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Benzatropine is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Benzatropine can be decreased when combined with Venlafaxine.Approved
VoriconazoleThe metabolism of Benzatropine can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Benzatropine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Benzatropine can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Phillips, R.F.; US. Patent 2,595,405; May 6, 1952; assigned to Merck & Co., Inc.

General References
  1. Wszola BA, Newell KM, Sprague RL: Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol. 2001 Aug;9(3):285-96. [PubMed:11534539]
  2. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998 Apr;155(4):565-7. [PubMed:9546009]
External Links
Human Metabolome Database
HMDB14390
KEGG Compound
C06846
PubChem Compound
1201549
PubChem Substance
46505349
ChemSpider
16736541
BindingDB
50366775
ChEBI
3048
ChEMBL
CHEMBL1201203
Therapeutic Targets Database
DAP001460
PharmGKB
PA448591
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Benztropine
ATC Codes
N04AC01 — Benzatropine
AHFS Codes
  • 28:36.08 — Anticholinergic Agents
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBack Pain1
2CompletedTreatmentBack Pain / Sciatica1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Peripheral Nervous System Diseases1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentSchizophrenic Disorders1
Not AvailableTerminatedTreatmentDelusional Disorder / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1

Pharmacoeconomics

Manufacturers
  • Hikma farmaceutica (portugal) sa
  • Nexus pharmaceuticals inc
  • Pharmaforce inc
  • Lundbeck inc
  • Actavis totowa llc
  • Corepharma llc
  • Invagen pharmaceuticals inc
  • Lannett holdings inc
  • Mutual pharmaceutical co inc
  • Pliva inc
  • Quantum pharmics ltd
  • Usl pharma inc
  • Vintage pharmaceuticals llc
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous1 mg/mL
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
InjectionParenteral1 mg/mL
LiquidIntramuscular; Intravenous1 mg
SolutionIntramuscular; Intravenous1 mg
TabletOral2 mg
SolutionOral2 mg
TabletOral1 mg
TabletOral0.5 mg
Prices
Unit descriptionCostUnit
Cogentin 2 mg/2 ml ampule70.09USD ml
Benztropine 2 mg/2 ml ampule37.5USD ml
Benztropine 2 mg/2 ml vial33.0USD ml
Benztropine mesylate powder26.38USD g
Benztropine mes 2 mg tablet0.41USD tablet
Benztropine mes 1 mg tablet0.38USD tablet
Benztropine mes 0.5 mg tablet0.34USD tablet
Benztropine Mesylate 0.5 mg tablet0.27USD tablet
Benztropine Mesylate 1 mg tablet0.27USD tablet
Benztropine Mesylate 2 mg tablet0.26USD tablet
Apo-Benztropine 2 mg Tablet0.06USD tablet
Pms-Benztropine 2 mg Tablet0.05USD tablet
Pms-Benztropine 1 mg Tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)138-140Phillips, R.F.; US. Patent 2,595,405; May 6, 1952; assigned to Merck & Co., Inc.
water solubilityVery solubleNot Available
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00121 mg/mLALOGPS
logP4.47ALOGPS
logP4.19ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)9.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.24 m3·mol-1ChemAxon
Polarizability35.42 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9766
Blood Brain Barrier+0.9929
Caco-2 permeable+0.7912
P-glycoprotein substrateNon-substrate0.5145
P-glycoprotein inhibitor IInhibitor0.8428
P-glycoprotein inhibitor IINon-inhibitor0.9561
Renal organic cation transporterInhibitor0.8218
CYP450 2C9 substrateNon-substrate0.7188
CYP450 2D6 substrateNon-substrate0.5
CYP450 3A4 substrateSubstrate0.669
CYP450 1A2 substrateNon-inhibitor0.9383
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorInhibitor0.7739
CYP450 2C19 inhibitorNon-inhibitor0.871
CYP450 3A4 inhibitorNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8925
Ames testNon AMES toxic0.5994
CarcinogenicityNon-carcinogens0.9729
BiodegradationNot ready biodegradable0.8768
Rat acute toxicity2.5708 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6077
hERG inhibition (predictor II)Non-inhibitor0.534
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Tropane alkaloids / Benzylethers / Piperidines / N-alkylpyrrolidines / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Diphenylmethane / Benzylether / Tropane alkaloid / Piperidine / N-alkylpyrrolidine / Pyrrolidine / Tertiary amine / Tertiary aliphatic amine / Dialkyl ether / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound (CHEBI:3048)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Katz JL, Agoston GE, Alling KL, Kline RH, Forster MJ, Woolverton WL, Kopajtic TA, Newman AH: Dopamine transporter binding without cocaine-like behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents. Psychopharmacology (Berl). 2001 Apr;154(4):362-74. [PubMed:11349389]
  2. Kulkarni SS, Kopajtic TA, Katz JL, Newman AH: Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. Epub 2006 Feb 3. [PubMed:16460947]
  3. Reith ME, Berfield JL, Wang LC, Ferrer JV, Javitch JA: The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem. 2001 Aug 3;276(31):29012-8. Epub 2001 Jun 6. [PubMed:11395483]
  4. Simoni D, Roberti M, Rondanin R, Baruchello R, Rossi M, Invidiata FP, Merighi S, Varani K, Gessi S, Borea PA, Marino S, Cavallini S, Bianchi C, Siniscalchi A: Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter. Bioorg Med Chem Lett. 2001 Mar 26;11(6):823-7. [PubMed:11277529]
  5. Todd CL, Grace AA: Interaction of benztropine and haloperidol actions on rat substantia nigra dopamine cell electrophysiological activity in vivo. Brain Res Bull. 1999 Jan 15;48(2):219-22. [PubMed:10230713]
  6. Zou MF, Kopajtic T, Katz JL, Wirtz S, Justice JB Jr, Newman AH: Novel tropane-based irreversible ligands for the dopamine transporter. J Med Chem. 2001 Dec 6;44(25):4453-61. [PubMed:11728190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Kulkarni SS, Kopajtic TA, Katz JL, Newman AH: Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. Epub 2006 Feb 3. [PubMed:16460947]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34